FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Data submitted by Theravance/Astellas in response to an October FDA “approvable” letter for the antibiotic could be behind the agency’s decision.